In Vitro High-Throughput Stem and Progenitor Cell Hematotoxicity Screening and Testing

At HemoGenix®, we pride ourselves on using the most advanced predictive hematotoxicity technology available. HALO®-Tox HT has been the predictive hematotoxicity platform of choice since 2001 and, together with our customizable and flexible quality services, this platform has been used by more than half of the top 50 biopharmaceutical companies worldwide.

Uses and Benefits of Using HALO®-Tox HT:

• The highest precision, reliability and reproducibility of any hematotoxicity testing service.

• Validated according to FDA Bioanalytical Method Validation Guidelines.

• Multiplex with other readouts.

• Available for individual stem and progenitor cell populations as well as “global” 4-, 5- and 7-population assays to provide predictability for the whole lympho-hematopoietic system from human, primate, dog, rat and mouse.

• High throughput capability for early drug development Tox-ADME screening.

• Greater than 80% in vitro to in vivo concordance.

• IND-enabling technology provides the highest level of trustworthy results.

• Studies usually completed within 5-7 days followed by a draft report in a total of 2 weeks.

For more information on our capabilities, contact us at contractresearch@hemogenix.com or call (719) 264-6250. Assay kits for in-house testing are available through our partner, www.preferred-cell-systems.com.